ID   EPHA5_RAT               Reviewed;        1005 AA.
AC   P54757;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   05-DEC-2018, entry version 165.
DE   RecName: Full=Ephrin type-A receptor 5;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH homology kinase 1;
DE            Short=EHK-1;
DE   Flags: Precursor;
GN   Name=Epha5; Synonyms=Ehk-1, Ekh1, Rek7;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
OC   Muroidea; Muridae; Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4 AND 5).
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=7504232;
RA   Maisonpierre P.C., Barrezueta N.X., Yancopoulos G.D.;
RT   "Ehk-1 and Ehk-2: two novel members of the Eph receptor-like tyrosine
RT   kinase family with distinctive structures and neuronal expression.";
RL   Oncogene 8:3277-3288(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=7898646; DOI=10.1016/0306-4522(94)90014-0;
RA   Taylor V., Miescher G.C., Pfarr S., Honegger P., Breitschopf H.,
RA   Lassmann H., Steck A.J.;
RT   "Expression and developmental regulation of Ehk-1, a neuronal Elk-like
RT   receptor tyrosine kinase in brain.";
RL   Neuroscience 63:163-178(1994).
RN   [3]
RP   FUNCTION IN AXON GUIDANCE, AND SUBCELLULAR LOCATION.
RX   PubMed=7748564; DOI=10.1016/0896-6273(95)90335-6;
RA   Winslow J.W., Moran P., Valverde J., Shih A., Yuan J.Q., Wong S.C.,
RA   Tsai S.P., Goddard A., Henzel W.J., Hefti F., Beck K.D., Caras I.W.;
RT   "Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor
RT   involved in axon bundle formation.";
RL   Neuron 14:973-981(1995).
RN   [4]
RP   FUNCTION IN SYNAPTIC PLASTICITY, AND TISSUE SPECIFICITY.
RX   PubMed=9698392; DOI=10.1006/mcne.1998.0696;
RA   Gao W.Q., Shinsky N., Armanini M.P., Moran P., Zheng J.L.,
RA   Mendoza-Ramirez J.L., Phillips H.S., Winslow J.W., Caras I.W.;
RT   "Regulation of hippocampal synaptic plasticity by the tyrosine kinase
RT   receptor, REK7/EphA5, and its ligand, AL-1/Ephrin-A5.";
RL   Mol. Cell. Neurosci. 11:247-259(1998).
RN   [5]
RP   FUNCTION IN SYNAPTOGENESIS, EFNA5 LIGAND-BINDING, SUBCELLULAR
RP   LOCATION, AND PHOSPHORYLATION.
RX   PubMed=20824214; DOI=10.1371/journal.pone.0012486;
RA   Akaneya Y., Sohya K., Kitamura A., Kimura F., Washburn C., Zhou R.,
RA   Ninan I., Tsumoto T., Ziff E.B.;
RT   "Ephrin-A5 and EphA5 interaction induces synaptogenesis during early
RT   hippocampal development.";
RL   PLoS ONE 5:E12486-E12486(2010).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously GPI-
CC       anchored ephrin-A family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into
CC       neighboring cells. The signaling pathway downstream of the
CC       receptor is referred to as forward signaling while the signaling
CC       pathway downstream of the ephrin ligand is referred to as reverse
CC       signaling. Among GPI-anchored ephrin-A ligands, EFNA5 most
CC       probably constitutes the cognate/functional ligand for EPHA5.
CC       Functions as an axon guidance molecule during development and may
CC       be involved in the development of the retinotectal, entorhino-
CC       hippocampal and hippocamposeptal pathways. Together with EFNA5
CC       plays also a role in synaptic plasticity in adult brain through
CC       regulation of synaptogenesis. In addition to its function in the
CC       nervous system, the interaction of EPHA5 with EFNA5 mediates
CC       communication between pancreatic islet cells to regulate glucose-
CC       stimulated insulin secretion (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:20824214, ECO:0000269|PubMed:7748564,
CC       ECO:0000269|PubMed:9698392}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-
CC         tyrosyl-[protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136,
CC         Rhea:RHEA-COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:46858, ChEBI:CHEBI:82620, ChEBI:CHEBI:456216;
CC         EC=2.7.10.1; Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The
CC       heterotetramer is composed of an ephrin dimer and a receptor
CC       dimer. Oligomerization is probably required to induce biological
CC       responses (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20824214,
CC       ECO:0000269|PubMed:7748564}; Single-pass type I membrane protein
CC       {ECO:0000255}. Cell projection, axon {ECO:0000269|PubMed:20824214,
CC       ECO:0000269|PubMed:7748564}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:P54756}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=P54757-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P54757-2; Sequence=VSP_003001;
CC       Name=3;
CC         IsoId=P54757-3; Sequence=VSP_003002;
CC         Note=Ref.2 (CAA55357) sequence differs from that shown due to
CC         several frameshifts. {ECO:0000305};
CC       Name=4;
CC         IsoId=P54757-4; Sequence=VSP_003002, VSP_003003;
CC       Name=5;
CC         IsoId=P54757-5; Sequence=VSP_003001, VSP_003002, VSP_003003;
CC   -!- TISSUE SPECIFICITY: Almost exclusively expressed in the nervous
CC       system. Predominantly expressed in neurons.
CC       {ECO:0000269|PubMed:9698392}.
CC   -!- PTM: Phosphorylated. Phosphorylation is stimulated by the ligand
CC       EFNA5. Dephosphorylation upon stimulation by glucose, inhibits
CC       EPHA5 forward signaling and results in insulin secretion (By
CC       similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
DR   EMBL; X78689; CAA55357.1; ALT_FRAME; mRNA.
DR   PIR; PT0186; PT0186.
DR   PIR; S47489; S47489.
DR   PIR; S49015; S49015.
DR   PIR; S51603; S51603.
DR   PIR; S51604; S51604.
DR   RefSeq; NP_077343.1; NM_024367.1.
DR   SMR; P54757; -.
DR   STRING; 10116.ENSRNOP00000002793; -.
DR   GuidetoPHARMACOLOGY; 1825; -.
DR   iPTMnet; P54757; -.
DR   PhosphoSitePlus; P54757; -.
DR   SwissPalm; P54757; -.
DR   PaxDb; P54757; -.
DR   PRIDE; P54757; -.
DR   GeneID; 79208; -.
DR   KEGG; rno:79208; -.
DR   UCSC; RGD:620831; rat. [P54757-1]
DR   CTD; 2044; -.
DR   RGD; 620831; Epha5.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000233856; -.
DR   InParanoid; P54757; -.
DR   KO; K05106; -.
DR   PhylomeDB; P54757; -.
DR   BRENDA; 2.7.10.1; 5301.
DR   PRO; PR:P54757; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0030425; C:dendrite; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005003; F:ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; ISS:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IBA:GO_Central.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; IDA:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0021766; P:hippocampus development; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IDA:MGI.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IBA:GO_Central.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IBA:GO_Central.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:0061178; P:regulation of insulin secretion involved in cellular response to glucose stimulus; ISS:UniProtKB.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM01411; Ephrin_rec_like; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Cell projection;
KW   Complete proteome; Glycoprotein; Kinase; Membrane; Neurogenesis;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL        1     26       {ECO:0000250}.
FT   CHAIN        27   1005       Ephrin type-A receptor 5.
FT                                /FTId=PRO_0000016814.
FT   TOPO_DOM     27    575       Extracellular. {ECO:0000255}.
FT   TRANSMEM    576    596       Helical. {ECO:0000255}.
FT   TOPO_DOM    597   1005       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       62    240       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      359    469       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      470    564       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      677    938       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      967   1005       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     683    691       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS    222    356       Cys-rich.
FT   ACT_SITE    802    802       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     709    709       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     652    652       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     658    658       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     835    835       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000255}.
FT   MOD_RES     984    984       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD    266    266       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    301    301       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    371    371       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    425    425       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    438    438       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    463    463       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT                                /FTId=VSP_003000.
FT   VAR_SEQ     306    357       VCRPGFFKASPHSQTCSKCPPHSYTHEEASTSCVCEKDYFR
FT                                RESDPPTMACT -> G (in isoform 2 and
FT                                isoform 5). {ECO:0000303|PubMed:7504232}.
FT                                /FTId=VSP_003001.
FT   VAR_SEQ     358    470       RPPSAPRNAISNVNETSVFLEWIPPADTGGGKDVSYYILCK
FT                                KCNSHAGVCEECGGHVRYLPQQIGLKNTSVMMADPLAHTNY
FT                                TFEIEAVNGVSDLSPGTRQYVSVNVTTNQAA -> T (in
FT                                isoform 3, isoform 4 and isoform 5).
FT                                {ECO:0000303|PubMed:7504232,
FT                                ECO:0000303|PubMed:7898646}.
FT                                /FTId=VSP_003002.
FT   VAR_SEQ     597    621       SGSCCECGCGRASSLCAVAHPSLIW -> R (in
FT                                isoform 4 and isoform 5).
FT                                {ECO:0000303|PubMed:7504232}.
FT                                /FTId=VSP_003003.
FT   CONFLICT    170    170       D -> E (in Ref. 2; CAA55357).
FT                                {ECO:0000305}.
FT   CONFLICT    566    566       G -> A (in Ref. 2; CAA55357).
FT                                {ECO:0000305}.
FT   CONFLICT    578    578       G -> A (in Ref. 2; CAA55357).
FT                                {ECO:0000305}.
FT   CONFLICT    669    669       G -> A (in Ref. 2; CAA55357).
FT                                {ECO:0000305}.
FT   CONFLICT    708    708       T -> I (in Ref. 2; CAA55357).
FT                                {ECO:0000305}.
FT   CONFLICT    979    979       T -> I (in Ref. 2; CAA55357).
FT                                {ECO:0000305}.
**
**   #################    INTERNAL SECTION    ##################
**DR PROSITE; PS00107; PROTEIN_KINASE_ATP; FALSE_NEG.
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:P54756; ANS; 19-NOV-2015.
**EV ECO:0000255; -; ANS; 19-NOV-2015.
**EV ECO:0000255; PROSITE-ProRule:PRU00159; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00184; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00316; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00883; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU10028; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:20824214; ANS; 24-JUL-2018.
**EV ECO:0000269; PubMed:7748564; ANS; 19-NOV-2015.
**EV ECO:0000269; PubMed:9698392; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:7504232; XXX; 01-JAN-1900.
**EV ECO:0000303; PubMed:7898646; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**ZB KAX, 14-MAR-2006; MCB, 31-JUL-2007; ANS, 24-JUL-2018;
**ZC LIB, 23-AUG-2011; Major revision.
SQ   SEQUENCE   1005 AA;  111007 MW;  1AED42C99693C574 CRC64;
     MRGSGPRGAG RRRTQGRGGG GDTPRVPASL AGCYSAPLKG PLWTCLLLCA ALRTLLASPS
     NEVNLLDSRT VLGDLGWIAF PKNGWEEIGE VDENYAPIHT YQVCKVMEQN QNNWLLTSWI
     SNEGASRIFI ELKFTLRDCN SLPGGLGTCK ETFNMYYFES DDENGRNIKD NQYIKIDTIA
     ADESFTELDL GDRVMKLNTE VRDVGPLSKK GFYLAFQDVG ACIALVSVRV YYKKCPSVVR
     HLAVFPDTIT GADSSQLLEV SGSCVNHSVT DDPPKMHCSA EGEWLVPIGK CMCKAGYEEK
     NGTCQVCRPG FFKASPHSQT CSKCPPHSYT HEEASTSCVC EKDYFRRESD PPTMACTRPP
     SAPRNAISNV NETSVFLEWI PPADTGGGKD VSYYILCKKC NSHAGVCEEC GGHVRYLPQQ
     IGLKNTSVMM ADPLAHTNYT FEIEAVNGVS DLSPGTRQYV SVNVTTNQAA PSPVTNVKKG
     KIAKNSISLS WQEPDRPNGI ILEYEIKYFE KDQETSYTII KSKETTITAE GLKPASVYVF
     QIRARTAAGY GVFSRRFEFE TTPVFGASND QSQIPIIGVS VTVGVILLAV MIGFLLSGSC
     CECGCGRASS LCAVAHPSLI WRCGYSKAKQ DPEEEKMHFH NGHIKLPGVR TYIDPHTYED
     PTQAVHEFGK EIEASCITIE RVIGAGEFGE VCSGRLKLPG KRELPVATKT LKVGYTEKQR
     RDFLSEASIM GQFDHPNIIH LEGVVTKSKP VMIVTEYMEN GSLDTFLKKN DGQFTVIQLV
     GMLRGIAAGM KYLSDMGYVH RDLAARNILI NSNLVCKVSD FGLSRVLEDD PEAAYTTRGG
     KIPIRWTAPE AIAFRKFTSA SDVWSYGIVM WEVVSYGERP YWEMTNQDVI KAVEEGYRLP
     SPMDCPAALY QLMLDCWQKD RNSRPKFDDI VNMLDKLIRN PSSLKTLVNA SSRVSTLLAE
     HGSLGSGAYR SVGEWLEATK MGRYTEIFME NGYSSMDAVA QVTLE
//
